Wednesday, 4 December 2013

Admissions avoidance and diabetes

Guidance for clinical commissioning groups and clinical teams (JBDS – IP)


Pathophysiology and treatment of type 2 diabetes

Perspectives on the past, present, and future (The Lancet)


Co-Stimulation Modulation with Abatacept in Patients with Recent-Onset Type 1 Diabetes: Follow-Up One Year After Cessation of Treatment

Co-stimulation modulation with abatacept slowed decline of beta-cell function and improved HbA1c in recent-onset T1DM. The beneficial effect was sustained for at least one year after cessation of abatacept infusions, or three years from T1DM diagnosis (Diabetes Care)

No comments:

Post a Comment